AR125321A2 - Compuesto cristalino, método de preparación y composición que lo comprende - Google Patents
Compuesto cristalino, método de preparación y composición que lo comprendeInfo
- Publication number
- AR125321A2 AR125321A2 ARP220100895A ARP220100895A AR125321A2 AR 125321 A2 AR125321 A2 AR 125321A2 AR P220100895 A ARP220100895 A AR P220100895A AR P220100895 A ARP220100895 A AR P220100895A AR 125321 A2 AR125321 A2 AR 125321A2
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline compound
- preparation
- composition including
- compound
- crystalline
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Un compuesto cristalino que tiene la fórmula (1). También se divulgan métodos de elaboración y composiciones que lo comprenden. Reivindicación 1: Un compuesto cristalino caracterizado porque tiene la fórmula (1). Reivindicación 35: Un método para transformar el compuesto cristalino de la reivindicación 11 en el compuesto cristalino de la reivindicación 19, caracterizado porque el método comprende la cristalización desde una forma solubilizada del Compuesto 1 o la conversión en suspensión. Reivindicación 38: Una composición farmacéutica caracterizada porque comprende una forma cristalina de cualquiera de las reivindicaciones precedentes, y un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125321A2 true AR125321A2 (es) | 2023-07-05 |
Family
ID=59772778
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102330A AR109393A1 (es) | 2016-08-23 | 2017-08-23 | Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino |
| ARP220100895A AR125321A2 (es) | 2016-08-23 | 2022-04-08 | Compuesto cristalino, método de preparación y composición que lo comprende |
| ARP220100894A AR125320A2 (es) | 2016-08-23 | 2022-04-08 | Compuesto cristalino, método de preparación y composición que lo comprende |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102330A AR109393A1 (es) | 2016-08-23 | 2017-08-23 | Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100894A AR125320A2 (es) | 2016-08-23 | 2022-04-08 | Compuesto cristalino, método de preparación y composición que lo comprende |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11236121B2 (es) |
| EP (2) | EP3504189A1 (es) |
| JP (2) | JP2019524853A (es) |
| KR (2) | KR20230079470A (es) |
| CN (4) | CN110088091A (es) |
| AR (3) | AR109393A1 (es) |
| AU (3) | AU2017315682B2 (es) |
| BR (1) | BR112019003637A2 (es) |
| CA (1) | CA3034262A1 (es) |
| CL (2) | CL2019000477A1 (es) |
| CO (1) | CO2019002596A2 (es) |
| EA (1) | EA201990565A1 (es) |
| EC (1) | ECSP19020141A (es) |
| IL (1) | IL302480A (es) |
| JO (1) | JOP20190022B1 (es) |
| MA (1) | MA46042A (es) |
| MX (2) | MX2019002193A (es) |
| PE (1) | PE20190915A1 (es) |
| PH (1) | PH12019500375A1 (es) |
| SG (1) | SG11201901445TA (es) |
| TW (2) | TWI808945B (es) |
| WO (1) | WO2018039378A1 (es) |
| ZA (1) | ZA201901051B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| CN108440633B (zh) | 2013-04-17 | 2021-07-13 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| ES2807264T3 (es) | 2013-04-17 | 2021-02-22 | Sage Therapeutics Inc | Esteroides neuroactivos 19-nor para métodos de tratamiento |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| HUE053900T2 (hu) | 2013-07-19 | 2021-07-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, kompozíciók, és azok alkalmazásai |
| BR112016003862B1 (pt) | 2013-08-23 | 2022-09-06 | Sage Therapeutics, Inc | Compostos esteroides neuroativos, suas composições e seus usos |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3206493B1 (en) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| SG10202009859YA (en) | 2014-10-16 | 2020-11-27 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| ME03749B (me) | 2014-11-27 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| WO2016134301A2 (en) | 2015-02-20 | 2016-08-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| DK3481845T3 (da) | 2016-07-11 | 2023-11-27 | Sage Therapeutics Inc | C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| JP2020533310A (ja) * | 2017-09-07 | 2020-11-19 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイドおよびそれらの使用方法 |
| EP3681510A1 (en) * | 2017-09-14 | 2020-07-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| SG11202012344RA (en) * | 2018-06-12 | 2021-01-28 | Sage Therapeutics Inc | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| US20230322846A9 (en) | 2018-12-05 | 2023-10-12 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| US20220098230A1 (en) * | 2019-01-31 | 2022-03-31 | Shenzhen Rentai Pharmatech Ltd. | y-AMINOBUTYRIC ACID MODULATOR CRYSTAL FORM X, PREPARATION METHOD AND APPLICATION THEREOF |
| WO2020242772A1 (en) | 2019-05-28 | 2020-12-03 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| JOP20210293A1 (ar) | 2019-05-31 | 2023-01-30 | Sage Therapeutics Inc | ستيرويدات ذات فعالية عصبية وتركيبات منها |
| US20220275020A1 (en) * | 2019-08-07 | 2022-09-01 | Shanghai Hansoh Biomedical Co., Ltd. | Salt and crystal form of steroid derivative regulator |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| JP2023519241A (ja) | 2020-03-25 | 2023-05-10 | セージ セラピューティクス， インコーポレイテッド | 呼吸器状態の処置のための薬剤の使用 |
| KR20230041049A (ko) | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
| AU2022214187A1 (en) | 2021-01-28 | 2023-07-13 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| KR20230158033A (ko) | 2021-03-17 | 2023-11-17 | 세이지 테라퓨틱스, 인크. | 주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| JP2024515830A (ja) | 2021-04-29 | 2024-04-10 | セージ セラピューティクス， インコーポレイテッド | 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド |
| MX2023012727A (es) | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. |
| IL309922A (en) | 2021-07-28 | 2024-03-01 | Sage Therapeutics Inc | Crystalline forms of a neuroactive steroid |
| WO2023158668A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| WO2023163879A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| JP2003519698A (ja) | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ，インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
| US7425567B2 (en) | 2002-02-08 | 2008-09-16 | Ono Pharmaceutical Co., Ltd. | Piperidine derivative compounds and drugs containing the compounds as the active ingredient |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| CA2892811A1 (en) | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression |
| US9676812B2 (en) | 2012-12-18 | 2017-06-13 | Washington University | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| CN108440633B (zh) | 2013-04-17 | 2021-07-13 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| SG10202009859YA (en) | 2014-10-16 | 2020-11-27 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| EP3206493B1 (en) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| CA2998134A1 (en) | 2015-09-08 | 2017-03-16 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| US20200306262A1 (en) | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| EP3426257A4 (en) | 2016-03-08 | 2019-11-13 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| DK3481845T3 (da) | 2016-07-11 | 2023-11-27 | Sage Therapeutics Inc | C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| US11285139B2 (en) | 2017-08-31 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Treatment of CNS conditions |
| JP2020533310A (ja) | 2017-09-07 | 2020-11-19 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイドおよびそれらの使用方法 |
| US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| EP3681510A1 (en) | 2017-09-14 | 2020-07-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| WO2019094724A1 (en) | 2017-11-10 | 2019-05-16 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| WO2019126761A1 (en) | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3728284A1 (en) | 2017-12-22 | 2020-10-28 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3737687A1 (en) | 2018-01-12 | 2020-11-18 | Sage Therapeutics, Inc. | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders |
| SG11202012344RA (en) | 2018-06-12 | 2021-01-28 | Sage Therapeutics Inc | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| AR116695A1 (es) | 2018-10-12 | 2021-06-02 | Sage Therapeutics Inc | Los neuroesteroides y sus métodos de uso |
| CA3116892A1 (en) | 2018-10-19 | 2020-04-23 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| US20230322846A9 (en) | 2018-12-05 | 2023-10-12 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| US20220372067A1 (en) | 2018-12-21 | 2022-11-24 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| TW202110824A (zh) | 2019-05-24 | 2021-03-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| JOP20210293A1 (ar) | 2019-05-31 | 2023-01-30 | Sage Therapeutics Inc | ستيرويدات ذات فعالية عصبية وتركيبات منها |
| US20230018765A1 (en) | 2019-12-05 | 2023-01-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| CA3175324A1 (en) | 2020-03-18 | 2021-09-23 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| JP2023519241A (ja) | 2020-03-25 | 2023-05-10 | セージ セラピューティクス， インコーポレイテッド | 呼吸器状態の処置のための薬剤の使用 |
| KR20230041049A (ko) | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
-
2017
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/en not_active Withdrawn
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es unknown
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 TW TW112101437A patent/TW202342059A/zh unknown
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt active Search and Examination
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko not_active Application Discontinuation
- 2017-08-23 MX MX2019002193A patent/MX2019002193A/es unknown
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Application Discontinuation
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/en active Pending
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/en active Application Filing
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 CA CA3034262A patent/CA3034262A1/en active Pending
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
-
2023
- 2023-08-24 US US18/455,324 patent/US20230399357A1/en active Pending
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125321A2 (es) | Compuesto cristalino, método de preparación y composición que lo comprende | |
| MX2019001096A (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| EA201891489A1 (ru) | Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
| CN106536480A8 (zh) | 吡咯烷‑2,5‑二酮衍生物、药物组合物及用作ido1抑制剂的方法 | |
| MX2021005052A (es) | Oxiesteroles y métodos de uso de los mismos. | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| EA201990455A1 (ru) | КОНДЕНСИРОВАННОЕ ТРИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ γ-АМИНОКИСЛОТЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ | |
| WO2015104658A3 (en) | Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin | |
| TN2017000031A1 (en) | Imidazopyridazine compounds | |
| SG10201902203VA (en) | Eutectic formulations of cyclobenzaprine hydrochloride | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| MX2017016619A (es) | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. | |
| MX2017003928A (es) | Composiciones farmaceuticas de accion prolongada. | |
| PH12020550125A1 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| PH12019500822A1 (en) | Crystalline forms of eravacycline | |
| PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
| EA201890075A1 (ru) | Инъецируемые фармацевтические композиции лефамулина | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| WO2016116882A3 (en) | Novel compositions of carfilzomib | |
| MX2017008983A (es) | Composición farmaceútica de sulfonamida. |